Published in BMC Bioinformatics on February 06, 2016
A simple method for displaying the hydropathic character of a protein. J Mol Biol (1982) 150.65
Structure validation by Calpha geometry: phi,psi and Cbeta deviation. Proteins (2003) 32.38
Pyrethroid resistance in African anopheline mosquitoes: what are the implications for malaria control? Trends Parasitol (2010) 8.80
The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc (2015) 8.53
The I-TASSER Suite: protein structure and function prediction. Nat Methods (2015) 6.17
European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect (2014) 3.33
Thermostability and aliphatic index of globular proteins. J Biochem (1980) 2.80
Correlation between stability of a protein and its dipeptide composition: a novel approach for predicting in vivo stability of a protein from its primary sequence. Protein Eng (1990) 2.73
Recent progress in mucosal vaccine development: potential and limitations. Nat Rev Immunol (2012) 2.65
VEGA--an open platform to develop chemo-bio-informatics applications, using plug-in architecture and script programming. J Comput Aided Mol Des (2004) 2.41
CelTOS, a novel malarial protein that mediates transmission to mosquito and vertebrate hosts. Mol Microbiol (2006) 1.84
Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum. Curr Opin Infect Dis (2011) 1.68
Control of protein functional dynamics by peptide linkers. Biopolymers (2005) 1.61
Immunology of gut mucosal vaccines. Immunol Rev (2011) 1.59
Significance of root-mean-square deviation in comparing three-dimensional structures of globular proteins. J Mol Biol (1994) 1.55
The future of interleukin-2: enhancing therapeutic anticancer vaccines. Cancer J Sci Am (2000) 1.52
Structure-function analysis of human interleukin-2. Identification of amino acid residues required for biological activity. J Biol Chem (1987) 1.43
Immune mechanisms in malaria: new insights in vaccine development. Nat Med (2013) 1.40
Immunization with pre-erythrocytic antigen CelTOS from Plasmodium falciparum elicits cross-species protection against heterologous challenge with Plasmodium berghei. PLoS One (2010) 1.24
Mucosal vaccine adjuvants update. Clin Exp Vaccine Res (2012) 1.15
Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. Curr Top Microbiol Immunol (2012) 1.13
Cellular and humoral immune effector mechanisms required for sterile protection against sporozoite challenge induced with the novel malaria vaccine candidate CelTOS. Vaccine (2011) 1.03
Target identification and validation of novel antimalarials. Future Microbiol (2011) 1.00
The M cell-targeting ligand promotes antigen delivery and induces antigen-specific immune responses in mucosal vaccination. J Immunol (2010) 0.97
The evil circle of poverty: a qualitative study of malaria and disability. Malar J (2012) 0.95
Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine. Proc Natl Acad Sci U S A (1989) 0.95
Advances and challenges in mucosal adjuvant technology. Vaccine (2015) 0.88
The Role of Dendritic Cell Subsets and Innate Immunity in the Pathogenesis of Type 1 Diabetes and Other Autoimmune Diseases. Front Immunol (2015) 0.85
Immunogenicity of oral vaccination with Lactococcus lactis derived vaccine candidate antigen (UreB) of Helicobacter pylori fused with the human interleukin 2 as adjuvant. Mol Cell Probes (2013) 0.81
Mucosal vaccines: where do we stand? Curr Top Med Chem (2013) 0.80
Efficacy of a bovine Staphylococcus aureus vaccine using interleukin-2 as an adjuvant. Zentralbl Veterinarmed B (1997) 0.77